Entacapone

Chemical formula: C₁₄H₁₅N₃O₅  Molecular mass: 305.286 g/mol  PubChem compound: 5281081

Therapeutic indications

Entacapone is indicated for:

Parkinson's disease

Population group: only adults (18 years old or older)

Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in adult patients with Parkinson’s disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Entacapone is contraindicated in the following cases:

Hepatic impairment, phaeochromocytoma, neuroleptic malignant syndrome (NMS), non-traumatic rhabdomyolysis

at least one of
Hepatic insufficiency
Phaeochromocytoma
Neuroleptic malignant syndrome
Non-traumatic rhabdomyolysis

Non-selective monoamine oxidase (MAO-A and MAO-B), selective MAO-A inhibitor plus a selective MAO-B inhibitor

at least one of
Non selective Monoamine Oxidase Inhibitors
Selective Monoamine Oxidase Inhibitors A and additionally Selective Monoamine Oxidase Inhibitors B

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: COMTAN Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈